Zelboraf Alternatives Compared
| Zelboraf | Yervoy | Mekinist |
|
|---|
| Zelboraf vemurafenib | Yervoy ipilimumab | Mekinist trametinib |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescribed for Erdheim-Chester Disease, Melanoma - Metastatic. Zelboraf may also be used for purposes not listed in this medication guide. |
Prescribed for Renal Cell Carcinoma, Melanoma - Metastatic, Colorectal Cancer, Melanoma, Malignant Pleural Mesothelioma. Yervoy may also be used for purposes not listed in this medication guide. |
Prescribed for Thyroid Cancer, Melanoma - Metastatic, Non-Small Cell Lung Cancer. Mekinist may also be used for purposes not listed in this medication guide. |
Choose a suggestion below Melanoma, Metastatic
Popular Comparisons
|
|||||||||||||||||||||||
| More about Zelboraf (vemurafenib) | More about Yervoy (ipilimumab) | More about Mekinist (trametinib) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
No lower-cost generic available |
||||||||||||||||||||||||
| Availability | ||||||||||||||||||||||||||
|
Prescription only |
Prescription only |
Prescription only |
||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Zelboraf has an average rating of 6.3 out of 10 from a total of 4 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 25% reported a negative effect. |
Be the first to share your experience with this drug. |
Mekinist has an average rating of 6.0 out of 10 from a total of 1 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 50% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
Common side effects include: squamous cell carcinoma, keratoacanthoma, skin photosensitivity, erythema of skin. See the full Zelboraf side effects document. |
See the full Yervoy side effects document. |
Common side effects include: acneiform eruption, cardiomyopathy, decreased left ventricular ejection fraction, dermatitis, palmar-plantar erythrodysesthesia, skin rash, erythema of skin. See the full Mekinist side effects document. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Zelboraf prices |
View all Yervoy prices |
View all Mekinist prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
120 hours |
352.8 hours |
115.2 hours |
||||||||||||||||||||||||
| CSA Schedule** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full Pregnancy Warnings document. |
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
Category D
Positive evidence of risk
See the full Pregnancy Warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 561 drugs are known to interact with Zelboraf:
|
A total of 139 drugs are known to interact with Yervoy:
|
A total of 17 drugs are known to interact with Mekinist:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 17, 2011 |
March 25, 2011 |
May 29, 2013 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.